JNCI Cancer Spectrum最新文献

筛选
英文 中文
Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019. 2010 年至 2019 年诊断前列腺癌时的年龄和前列腺特异性抗原趋势。
IF 3.4
JNCI Cancer Spectrum Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae106
Lukas Owens, Ojas Brahme, Roman Gulati, Ruth Etzioni
{"title":"Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019.","authors":"Lukas Owens, Ojas Brahme, Roman Gulati, Ruth Etzioni","doi":"10.1093/jncics/pkae106","DOIUrl":"10.1093/jncics/pkae106","url":null,"abstract":"<p><p>Recent studies have shown that de novo metastatic prostate cancer incidence in the United States increased from 2010 to 2019. Plausible explanations include delayed detection after recommendations against prostate cancer screening or upstaging associated with use of more sensitive imaging technologies. Using Surveillance, Epidemiology, and End Results patient cases and controlling for aging of the population, we found the median age and prostate-specific antigen (PSA) level at prostate cancer diagnosis increased by 1.4 years of age (95% CI = 1.3 to 1.5 years) and 1.4 ng/mL (95% CI = 1.4 to 1.5 ng/mL) over this period, consistent with the delayed detection hypothesis. Racial differences were noted, with 75th percentiles of PSA at diagnosis increasing by 4.3 ng/mL (95% CI = 3.7 to 4.8 ng/mL) over this time period for non-Hispanic Black men compared with 3.0 ng/mL (95% CI = 2.8 to 3.2 ng/mL) for non-Hispanic White men. Overall, patient characteristics at diagnosis suggest that delayed detection contributed at least in part to increases in de novo metastatic disease.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11578289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Posttreatment surveillance intensity and overall survival in prostate cancer survivors (AFT-30). 前列腺癌幸存者的治疗后监测强度和总生存率(AFT-30)。
IF 4.3
JNCI Cancer Spectrum Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae099
Ronald C Chen, Ramsankar Basak, Stacie Dusetzina, Deborah S Usinger, Zahed Mohammed, Aaron D Falchook, Jessica R Schumacher, Amanda B Francescatti, Amanda Cuddy, George J Chang, Benjamin D Kozower, Caprice C Greenberg, Anne K Barber, Aaron J Katz
{"title":"Posttreatment surveillance intensity and overall survival in prostate cancer survivors (AFT-30).","authors":"Ronald C Chen, Ramsankar Basak, Stacie Dusetzina, Deborah S Usinger, Zahed Mohammed, Aaron D Falchook, Jessica R Schumacher, Amanda B Francescatti, Amanda Cuddy, George J Chang, Benjamin D Kozower, Caprice C Greenberg, Anne K Barber, Aaron J Katz","doi":"10.1093/jncics/pkae099","DOIUrl":"10.1093/jncics/pkae099","url":null,"abstract":"<p><strong>Background: </strong>Posttreatment surveillance affects millions of cancer survivors, but empiric data to guide clinical practice are lacking. This study assessed whether the intensity of surveillance testing after radical prostatectomy or radiation therapy for localized prostate cancer is associated with overall survival.</p><p><strong>Methods: </strong>Men diagnosed with localized prostate cancer between 2005 and 2010 who underwent radical prostatectomy or radiation therapy at a Commission on Cancer-accredited facility were randomly sampled. Primary data collected from 10 147 patients sampled across 1007 facilities were linked with existing data from the National Cancer Database. Analysis examined whether intensity of surveillance measured as the number of prostate-specific antigen (PSA) tests in the first year after primary treatment (categorized as 0-1 [low intensity], 2 [medium], or ≥3 [high intensity] PSA tests) was associated with overall survival. Secondary outcomes included recurrence-free survival (RFS) and subsequent use of imaging tests, biopsy procedures, and salvage treatment.</p><p><strong>Results: </strong>Median follow-up exceeded 8 years from prostate cancer diagnosis. Overall survival was not statistically significantly different across surveillance intensity groups among radiation therapy (P = .59) or radical prostatectomy (P = .29) patients. RFS was not statistically significantly different across surveillance intensity groups for radiation therapy (P = .13) patients but was for radical prostatectomy (P = .01) patients with high intensity associated with the worst RFS. In both treatments, higher surveillance intensity was associated with more procedures and salvage treatments.</p><p><strong>Conclusions: </strong>In patients with localized prostate cancer, more frequent PSA surveillance testing after radical prostatectomy or radiation therapy was associated with increased procedures and salvage treatments but not overall survival.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis. 化疗对错配修复缺陷晚期子宫内膜癌患者的影响--一项荟萃分析。
IF 3.4
JNCI Cancer Spectrum Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae101
Angelina Tjokrowidjaja, Peey-Sei Kok, Yoland C Antill, Clare L Scott, Linda R Mileshkin, Michael L Friedlander, Chee K Lee
{"title":"Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis.","authors":"Angelina Tjokrowidjaja, Peey-Sei Kok, Yoland C Antill, Clare L Scott, Linda R Mileshkin, Michael L Friedlander, Chee K Lee","doi":"10.1093/jncics/pkae101","DOIUrl":"10.1093/jncics/pkae101","url":null,"abstract":"<p><strong>Background: </strong>Chemo-immunotherapy is standard of care for women with recurrent or advanced mismatch repair deficient endometrial carcinoma. However, it is uncertain whether patients with mismatch repair deficient advanced or recurrent endometrial carcinoma derive less benefit from chemotherapy than those with mismatch repair proficient endometrial carcinoma.</p><p><strong>Methods: </strong>We performed a meta-analysis of randomized controlled trials (RCTs) in advanced or recurrent endometrial carcinoma to determine the difference in the benefit of chemotherapy in mismatch repair deficient vs mismatch repair proficient endometrial carcinoma. Data on chemotherapy outcomes including objective response rate, progression-free survival (PFS), and overall survival were retrieved. We pooled these data using the inverse variance method and examined subgroup difference by mismatch repair status. We also compared differences in PFS and overall survival outcomes by creating individual patient data from the Kaplan-Meier curves of trial publications for sensitivity analyses.</p><p><strong>Results: </strong>A total of 5 RCTs with 1137 participants (mismatch repair deficient, 26%; mismatch repair proficient, 74%) were included. All participants were treated with carboplatin-based chemotherapy. There was no difference between the mismatch repair deficient and mismatch repair proficient subgroups for objective response rate (66.5% vs 64.0%; P = .20 for subgroup difference), PFS (hazard ratio [HR] = 0.93, 95% confidence interval [CI] = 0.77 to 1.12; P = .44; median PFS = 7.6 vs 9.5 months) or overall survival (HR = 1.03, 95% CI = 0.73 to 1.44; P = .88; median overall survival = not reached vs 28.6 months).</p><p><strong>Conclusions: </strong>Objective response rate, PFS, and overall survival were similar among those with mismatch repair deficient vs mismatch repair proficient endometrial cancer treated with front-line, platinum-doublet chemotherapy in RCTs. These findings reinforce the importance of combining chemotherapy together with immune checkpoint inhibitors until the results of trials comparing immune checkpoint therapy alone with combination therapy are available.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Randomized pilot trial of an unconditional cash transfer intervention to address food insecurity in oncology. 无条件现金转移干预的随机试点试验,以解决肿瘤患者的粮食不安全问题。
IF 3.4
JNCI Cancer Spectrum Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae107
Jean A McDougall, Shoshana Adler Jaffe, Kendal Jacobson, Tori L Shaver, Jennifer L F Wilson, Katrina Baca, Tawny Boyce, Bernard Tawfik, Janet Page-Reeves
{"title":"Randomized pilot trial of an unconditional cash transfer intervention to address food insecurity in oncology.","authors":"Jean A McDougall, Shoshana Adler Jaffe, Kendal Jacobson, Tori L Shaver, Jennifer L F Wilson, Katrina Baca, Tawny Boyce, Bernard Tawfik, Janet Page-Reeves","doi":"10.1093/jncics/pkae107","DOIUrl":"10.1093/jncics/pkae107","url":null,"abstract":"<p><p>Screening for food insecurity and other social determinants of health is being integrated into oncology practice. We performed a pilot randomized trial to investigate whether an unconditional cash transfer (UCT) could be used to address food insecurity among female breast and gynecological cancer survivors. Food-insecure cancer survivors completed a baseline survey and were randomly assigned to receive $100/month for 3 months (UCT) or usual care (UC). Participants (n = 14) completed a follow-up survey after 3 months, and we compared changes in health-related quality of life, indicators of food insecurity, diet quality, and whether a participant had to forgo, delay, or make changes to medical care because of cost. The UCT was associated with higher physical health scores, fewer indicators of food insecurity, better diet quality, and a lower likelihood of forgoing medical care than those who received UC. Our results suggest that UCTs can improve outcomes for food-insecure cancer survivors.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung cancer-a one-way ticket. 肺癌--一张单程票
IF 3.4
JNCI Cancer Spectrum Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae098
Drew Moghanaki, Michelle Ann Eala, Jill Feldman, Terri Ann DiJulio, Peter Gorayski
{"title":"Lung cancer-a one-way ticket.","authors":"Drew Moghanaki, Michelle Ann Eala, Jill Feldman, Terri Ann DiJulio, Peter Gorayski","doi":"10.1093/jncics/pkae098","DOIUrl":"10.1093/jncics/pkae098","url":null,"abstract":"","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":"8 6","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neighborhood vulnerability and associations with poor health-related quality of life among adult survivors of childhood cancer. 儿童癌症成年幸存者的邻里脆弱性及与健康相关的生活质量低下的关联。
IF 3.4
JNCI Cancer Spectrum Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae088
Jaesung Choi, Madeline R Horan, Tara M Brinkman, D Kumar Srivastava, Kirsten K Ness, Gregory T Armstrong, Melissa M Hudson, I-Chan Huang
{"title":"Neighborhood vulnerability and associations with poor health-related quality of life among adult survivors of childhood cancer.","authors":"Jaesung Choi, Madeline R Horan, Tara M Brinkman, D Kumar Srivastava, Kirsten K Ness, Gregory T Armstrong, Melissa M Hudson, I-Chan Huang","doi":"10.1093/jncics/pkae088","DOIUrl":"10.1093/jncics/pkae088","url":null,"abstract":"<p><strong>Background: </strong>Few studies have investigated the relationship between neighborhood vulnerability and health-related quality of life (HRQOL) in the childhood cancer population. This study evaluated the impact of neighborhood vulnerability on HRQOL among adult survivors of childhood cancer.</p><p><strong>Methods: </strong>This cross-sectional study included 4393 adult survivors of childhood cancer from the St Jude Lifetime Cohort Study. At the baseline (2007-2020), HRQOL was assessed using the SF36v2's physical and mental components summaries (PCS and MCS). Neighborhood vulnerability was assessed using the overall, domain, and indicator-specific scores of the Social Vulnerability Index (SVI) and Minority Health SVI (MHSVI). Multivariable logistic regression was used to evaluate associations of neighborhood vulnerability (quartiles: Q1-Q4) with impaired HRQOL (1SD below the norm), adjusting for diagnosis, demographics, personal socioeconomic status (SES), lifestyle, and chronic health condition burden. Interactions of SVI and MHSVI with personal SES on impaired HRQOL were analyzed.</p><p><strong>Results: </strong>Among survivors, 51.9% were male, averaging 30.3 years of age at evaluation and 21.5 years since diagnosis. Comparing neighborhoods with higher vs lower vulnerability (Q4 vs Q1), overall (odds ratio [OR] = 1.60, 95% confidence interval [CI] = 1.19 to 2.16) and domain-specific vulnerability (socioeconomic: OR = 1.59, 95% CI = 1.18 to 2.15; household composition: OR = 1.54, 95% CI = 1.16 to 2.06; housing and transportation: OR = 1.33, 95% CI = 1.00 to 1.76; medical vulnerability: OR = 1.60, 95% CI = 1.22 to 2.09) were significantly associated with impaired PCS, but not MCS. Residing in neighborhoods lacking urgent care clinics was significantly associated with impaired PCS (OR = 1.39, 95% CI = 1.08 to 1.78). Having lower vs higher personal education and living in higher vulnerability neighborhoods were associated with more impaired PCS (Pinteraction = .021).</p><p><strong>Conclusions: </strong>Specific aspects of neighborhood vulnerability increase the risk for impaired physical HRQOL. Addressing these neighborhood factors is essential to enhance the HRQOL of survivors.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low CD86 expression is a predictive biomarker for clinical response to the therapeutic human papillomavirus vaccine IGMKK16E7: results of a post hoc analysis. 低 CD86 表达是治疗性 HPV 疫苗 IGMKK16E7 临床反应的预测性生物标志物:事后分析的结果。
IF 3.4
JNCI Cancer Spectrum Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae091
Hanano Ando, Yuki Katoh, Osamu Kobayashi, Yuji Ikeda, Hideaki Yahata, Takashi Iwata, Toyomi Satoh, Azusa Akiyama, Daichi Maeda, Yumiko Hori-Hirose, Yukari Uemura, Kaori Nakayama-Hosoya, Kanoko Katoh, Takahiro Nakajima, Ayumi Taguchi, Atsushi Komatsu, Saki Kamata, Naoko Tomita, Kiyoko Kato, Daisuke Aoki, Shizunobu Igimi, Ai Kawana-Tachikawa, Danny J Schust, Kei Kawana
{"title":"Low CD86 expression is a predictive biomarker for clinical response to the therapeutic human papillomavirus vaccine IGMKK16E7: results of a post hoc analysis.","authors":"Hanano Ando, Yuki Katoh, Osamu Kobayashi, Yuji Ikeda, Hideaki Yahata, Takashi Iwata, Toyomi Satoh, Azusa Akiyama, Daichi Maeda, Yumiko Hori-Hirose, Yukari Uemura, Kaori Nakayama-Hosoya, Kanoko Katoh, Takahiro Nakajima, Ayumi Taguchi, Atsushi Komatsu, Saki Kamata, Naoko Tomita, Kiyoko Kato, Daisuke Aoki, Shizunobu Igimi, Ai Kawana-Tachikawa, Danny J Schust, Kei Kawana","doi":"10.1093/jncics/pkae091","DOIUrl":"10.1093/jncics/pkae091","url":null,"abstract":"<p><strong>Background: </strong>Although therapeutic human papillomavirus vaccines could offer a noninvasive treatment for patients with cervical intraepithelial neoplasia, none has been clinically implemented. Oral administration of the therapeutic human papillomavirus vaccine IGMKK16E7 results in the histological regression of human papillomavirus 16-positive cervical intraepithelial neoplasia 2/3 to normal (complete response). We investigated biomarkers that could predict complete response after oral administration of IGMKK16E7.</p><p><strong>Methods: </strong>Forty-two patients administered high-dose oral IGMKK16E7 in a phase I/II trial were included. Cervix-exfoliated cells were collected before vaccine administration. Gene expression of CD4, CD8, FOXP3, programmed cell death 1 protein, CTLA4, CD103, CD28, CD80, CD86, and programmed cell death 1 ligand 1 in the cells was measured by quantitative reverse transcriptase-polymerase chain reaction. Receiver operating characteristic curve analysis and Mann-Whitney tests were used to explore potential biomarkers. Pearson correlation coefficient analysis was used to correlate gene expression profiles with clinical outcome.</p><p><strong>Results: </strong>The only predictive biomarker of vaccine response for which receiver operating characteristic curve analysis showed significant diagnostic performance with histological complete response was CD86 (area under the curve = 0.71, 95% confidence interval = 0.53 to 0.88, P = .020). Patients with complete response had significantly lower CD86 expression (CD86-low) than patients with no complete response (P = .035). The complete response rates for CD86-low and CD86-high patients were 50% and 19%, respectively, and CD86-low patients had a significantly higher complete response rate (P = .047). Compared with all patients, the CD86-low group had a 1.5-fold increase in the complete response rate. Gene expression of CD86 and CTLA4 showed the strongest positive correlation with clinical outcomes in the incomplete response group (P < .001).</p><p><strong>Conclusion: </strong>Low expression of CD86 in exfoliated cervical cells can be used as a pretreatment biomarker to predict histological complete response after IGMKK16E7 administration.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The feasibility and acceptability of home phlebotomy for patients with cancer. 癌症患者居家抽血的可行性和可接受性。
IF 3.4
JNCI Cancer Spectrum Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae104
Erin M Bange, Camila Bernal, Kemi Bolutayo Gaffney, Jill Ackerman, David Kwong, Jithin Thomas, Bobby Daly
{"title":"The feasibility and acceptability of home phlebotomy for patients with cancer.","authors":"Erin M Bange, Camila Bernal, Kemi Bolutayo Gaffney, Jill Ackerman, David Kwong, Jithin Thomas, Bobby Daly","doi":"10.1093/jncics/pkae104","DOIUrl":"10.1093/jncics/pkae104","url":null,"abstract":"<p><p>Time toxicity is a considerable burden for oncology patients. This study evaluated the feasibility and acceptability of integrating mobile phlebotomy into standard of care procedures. From September 26, 2022, through December 31, 2023, a total of 345 patients had 1464 home laboratory test collection visits completed. These mobile phlebotomy laboratory collection visits occurred in New York (68.6% of visits), New Jersey (29.9%), Connecticut (1.1%), and Pennsylvania (0.5%). Specimen quality for home laboratory test collection surpassed the Memorial Sloan Kettering Department of Pathology and Laboratory Medicine benchmarks. Acceptability was high, 173 patients were approached, and 149 responded (86% response rate); most respondents (147 of 149, 99%) would use the service again or recommend it to others. This study assessed the integration of mobile phlebotomy into standard of care management for the collection of routine cancer laboratory tests. Mobile phlebotomy results in high patient satisfaction with superior specimen quality, offering a valuable solution to oncology patients for improved efficiency and convenience.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11547947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical guidelines for the management of mammographic density: a systematic review of breast screening guidelines worldwide. 乳腺造影密度管理的临床指南:全球乳腺筛查指南的系统回顾。
IF 3.4
JNCI Cancer Spectrum Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae103
Jennifer Marie Jacqueline Isautier, Nehmat Houssami, Claudia Hadlow, Michael Luke Marinovich, Serena Hope, Sophia Zackrisson, Meagan Elizabeth Brennan, Brooke Nickel
{"title":"Clinical guidelines for the management of mammographic density: a systematic review of breast screening guidelines worldwide.","authors":"Jennifer Marie Jacqueline Isautier, Nehmat Houssami, Claudia Hadlow, Michael Luke Marinovich, Serena Hope, Sophia Zackrisson, Meagan Elizabeth Brennan, Brooke Nickel","doi":"10.1093/jncics/pkae103","DOIUrl":"10.1093/jncics/pkae103","url":null,"abstract":"<p><strong>Background: </strong>High breast density is an independent risk factor for breast cancer and decreases the sensitivity of mammography. This systematic review synthesizes the international clinical guidelines and the evidence base for screening and supplemental screening recommendations in women with dense breasts.</p><p><strong>Methods: </strong>A systematic search of CINHAL, Embase, and Medline databases was performed in August 2023 and grey literature searched in January 2024. Two authors independently assessed study eligibility and quality (Appraisal of Guidelines for Research and Evaluation II instrument).</p><p><strong>Results: </strong>Of 3809 articles, 23 guidelines published from 2014 to 2024 were included. The content and quality varied between the guidelines; the average AGREE II total score was 58% (range = 23%-87%). Most guidelines recommended annual or biennial screening mammography for women more than 40 years old with dense breasts (n = 16). Other guidelines recommended breast tomosynthesis (DBT, n = 6) or magnetic resonance imaging (MRI, n = 1) as the preferred screening modality. One third of the guidelines (n = 8) did not recommend supplemental screening for women with dense breasts. Of those that recommended supplemental screening (n = 14), ultrasound was the preferred modality (n = 7), with MRI (n = 3), DBT (n = 3), and contrast-enhanced mammography (n = 2) also recommended.</p><p><strong>Conclusions: </strong>Consensus on supplemental screening in women with dense breasts is lacking. The quality of the guidelines is variable, and recommendations are based largely on low-quality evidence. As evidence of the benefits versus harms of supplemental screening in women with dense breasts is evolving, it is imperative to improve the methodological quality of breast cancer screening and supplemental screening guidelines.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11578290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of immunotherapy in gastroesophageal cancer with liver metastasis. 免疫疗法在胃食管癌肝转移中的作用
IF 3.4
JNCI Cancer Spectrum Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae105
Sawyer Bawek, Mrinalini Ramesh, Sayuri Gurusinghe, Ali Aijaz, Kristopher Attwood, Nariman Hossein-Javaheri, Sarbajit Mukherjee
{"title":"Role of immunotherapy in gastroesophageal cancer with liver metastasis.","authors":"Sawyer Bawek, Mrinalini Ramesh, Sayuri Gurusinghe, Ali Aijaz, Kristopher Attwood, Nariman Hossein-Javaheri, Sarbajit Mukherjee","doi":"10.1093/jncics/pkae105","DOIUrl":"10.1093/jncics/pkae105","url":null,"abstract":"<p><p>The role of immune checkpoint inhibitors for patients with gastroesophageal cancer with liver metastasis remains unclear. Our objective was to investigate whether immune checkpoint inhibitors are beneficial in patients with gastroesophageal cancer with liver metastasis. We searched PubMed, Embase, European Society for Medical Oncology, and American Society of Clinical Oncology meeting abstracts for phase 3 randomized clinical trials testing immune checkpoint inhibitors in metastatic/advanced gastroesophageal cancer from 2017 to 2023. Seven studies were included. Overall survival was similar among all patients (hazard ratio [HR] = 0.72 [95% confidence interval (CI) = 0.67 to 0.77], P < .001), in patients without liver metastases (HR = 0.73 [95% CI = 0.67 to 0.81], P < .001, I2 = 0.0%), and in patients with liver metastases (HR = 0.74 [95% CI = 0.67 to 0.81], P < .001, I2 = 0.0%). Progression-free survival was also similar among all patients (HR = 0.63 [95% CI = 0.57 to 0.70], P < .001), in patients without liver metastases (HR = 0.62 [95% CI = 0.51 to 0.76], P < .001), and in patients with liver metastases (HR = 0.66 [95% CI = 0.57 to 0.76], P < .001). Immune checkpoint inhibitors showed no difference in benefit in patients with gastroesophageal cancer, regardless of liver metastasis. Future studies could focus on deciphering the tumor microenvironment of liver metastasis as an area of translational research.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信